EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $4.50 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Price: $3.32 -2.35%
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $4.50 (from $2.75) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Boston Properties Inc. (BXP) PT Lowered to $70 at BMO Capital
- Neurocrine Bio. (NBIX) PT Lowered to $150 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
